Kevin Siewers, NP
Psychiatric/Mental Health · Staten Island, NYNPI 1215056221
Payments from drug & device makers
Across 760 payments — averaging $203.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$103K
- Otsuka America Pharmaceutical, Inc.$29K
- Teva Pharmaceuticals USA, Inc.$12K
- Alkermes, Inc.$6K
- Johnson & Johnson$1K
- Lundbeck LLC$854
- plus $3K from 14 others
What the payments were for
- Consulting fees$19,36313%
- Speaking & faculty fees$106,12869%
- Travel & lodging$7,8555%
- Food & beverage$21,04714%
- Education$2640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 157 | $102,712 |
| Otsuka America Pharmaceutical, Inc. | 182 | $28,599 |
| Teva Pharmaceuticals USA, Inc. | 96 | $12,471 |
| Alkermes, Inc. | 120 | $5,705 |
| Johnson & Johnson | 71 | $1,377 |
| Lundbeck LLC | 42 | $854 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 8 | $788 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $611 |
| AbbVie | 26 | $540 |
| E.r. Squibb & Sons, L.L.C. | 10 | $476 |
| Vanda Pharmaceuticals Inc. | 14 | $196 |
| Janssen Scientific Affairs, LLC | 1 | $88 |
| Corium, LLC | 2 | $62 |
| Indivior Inc. | 4 | $58 |
| Sunovion Pharmaceuticals Inc. | 2 | $37 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Tris Pharma Inc | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $15 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$100,584
- ABILIFY MAINTENA$25,069
- ABILIFY ASIMTUFII$22,553
- LYBALVI$13,652
- UZEDY$10,468
- REXULTI$1,478
- ARISTADA$847
- INVEGA SUSTENNA$469
- AUSTEDO$361
- Austedo XR$348
- INVEGA TRINZA$300
- COBENFY$258
- CAPLYTA$230
- ARISTADA INITIO$212
- VRAYLAR$123
- VIVITROL$119
How this compares
$154,656 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 52 | $436,166 |
| Abilify MaintenaAripiprazole | 116 | $324,501 |
| Invega SustennaPaliperidone Palmitate | 68 | $205,910 |
| RexultiBrexpiprazole | 72 | $124,055 |
| Invega TrinzaPaliperidone Palmitate | 17 | $118,358 |
| VraylarCariprazine Hcl | 45 | $66,892 |
| UzedyRisperidone | 19 | $61,974 |
| AristadaAripiprazole Lauroxil | 17 | $52,814 |
| LybalviOlanzapine/Samidorphan Malate | 32 | $50,397 |
| FanaptIloperidone | 12 | $26,495 |
| Fluphenazine Hcl | 53 | $12,598 |
| Aripiprazole | 320 | $11,148 |
| ZyprexaOlanzapine | 12 | $8,404 |
| Ambien CrZolpidem Tartrate | 12 | $7,610 |
| Paliperidone ErPaliperidone | 21 | $6,073 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $28,599 | $448,556188 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $102,712 | $436,16652 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $1,377 | $324,26885 claims |
| Alkermes, Inc.Aristada, Lybalvi | $5,705 | $103,21149 claims |
| AbbVieVraylar | $540 | $66,89245 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $12,471 | $61,97419 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $196 | $26,49512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Staten Island
- Glenn HannDansville$1.3M
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Daniel BreeyearNiskayuna$149K
- Mary OlsonNew York$142K
- Elijah StevensBinghamton$131K
- Kayanna JonasFar Rockaway$93K
- Alexis CrisafiFishkill$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.